c-Mpl Monoclonal Antibody (1H2), Invitrogen™

Description

• MA5-17127 targets MPL in indirect ELISA, FACS and WB applications and shows reactivity with Human samples
• The MA5-17127 immunogen is purified recombinant fragment of human MPL expressed in E
• Coli
• MA5-17127 detects MPL which has a predicted molecular weight of approximately 71.2kDa
• In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages
• In 1992 the human homologue, named, c-mpl, was cloned
• Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily
• Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation
• The ligand for c-mpl, thrombopoietin, was cloned in 1994
• Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation
• The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs
• TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation
• Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.